Medication info

Pregabalin Capsule 75mg (Pregabalin)

Prescription medicationHard capsuleOralExpired
Ingredient · strength
Pregabalin›75mg / 1 capsule
Manufacturer / importer
Daehan New Pharm Co., Ltd.
Appearance
A hard capsule with a reddish-brown upper part and a white lower part containing white powder.
Packaging
30 capsules/bottle, 100 capsules/bottle
Approval status
Expired

MFDS item code 201904606 · Approved 2019.07.08

This product's status changed to Expired on 2024.07.08. It may no longer be sold, so consult a doctor or pharmacist before taking it.

Summary

Main use
Treatment of neuropathic pain and fibromyalgia; adjunctive treatment of partial seizures
Who takes it
Adults · Children
Adult dose
This medicine is administered orally, with or without food, in 2 divided doses per day, for a total daily dose of pregabalin. Since this medicine is primarily excreted by the kidneys, the dose should be adjusted in patients with impaired renal function. (See “5. Patients with Renal Impairment”) 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of each patient, the dose may be increased to 300 mg/day after 3 to 7 days. If necessary, the dose may then be increased at 7-day intervals to a maximum of 600 mg/day. 2) Central neuropathic pain Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of each patient, the dose may be increased to 300 mg/day after 1 week. After an additional 1 week, the dose may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered. (See “4. Discontinuation of Treatment”) 2. Epilepsy Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of each patient, the dose may be increased to 300 mg/day after 1 week. If necessary, the dose may then be increased at 7-day intervals to a maximum of 600 mg/day. 3. Fibromyalgia The recommended dose of this medicine for fibromyalgia is 300 mg to 450 mg/day. The initial dose is 75 mg twice daily (150 mg/day), and based on efficacy and tolerability, it may be increased within 1 week to 150 mg twice daily (300 mg/day). For patients who do not experience sufficient benefit at a dose of 300 mg/day, the dose may be increased within 1 week to 225 mg twice daily (450 mg/day). Clinical studies have also been conducted at a dose of 600 mg/day; however, there is no evidence of additional benefit or adequate tolerability at this dose. In view of the dose-dependent adverse reactions, doses exceeding 450 mg/day are not recommended. 4. Discontinuation of Treatment Based on current clinical experience, if treatment with this medicine is discontinued, it should be tapered gradually over at least 1 week. 5. Patients with Renal Impairment After entering the systemic circulation, this medicine is primarily excreted by the kidneys unchanged. Since the clearance of this medicine is directly affected by creatinine clearance, dose reduction in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the formula below. This medicine is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients receiving hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, an immediate supplemental dose should be administered after each 4-hour hemodialysis session. [Table 1]. Pregabalin dosage based on renal function Creatinine clearance (CLcr), (mL/min) ≥60: Initial dose 150 (mg/day), maximum dose 600 (mg/day), BID or TID Creatinine clearance (CLcr), (mL/min) ≥30 -<60: Initial dose 75 (mg/day), maximum dose 300 (mg/day), BID or TID Creatinine clearance (CLcr), (mL/min) ≥15 -<30: Initial dose 25-50 (mg/day), maximum dose 150 (mg/day), QD or BID Creatinine clearance (CLcr), (mL/min) <15: Initial dose 25 (mg/day), maximum dose 75 (mg/day), QD Supplemental dose after hemodialysis: Initial dose 25, maximum dose 100, single dose b TID = total daily dose administered in 3 divided doses BID = total daily dose administered in 2 divided doses QD = administered once daily a: The total daily dose (mg/day) should be administered in divided doses as specified in the dosing regimen. b: A supplemental dose refers to an additional dose administered as a single dose. 6. Patients with Hepatic Impairment No dose adjustment is necessary in patients with hepatic impairment. 8. Older adults (aged 65 years or older) Dose reduction may be necessary in older adults with impaired renal function.
Child dose
7. Pediatric and adolescent patients Children under 12 years of age: Administration is not recommended because there are insufficient safety and efficacy data. Adolescent patients aged 12~17 years: Administration is not recommended because there are insufficient safety and efficacy data.

Ingredients

Manufacturer
Daehan New Pharm Co., Ltd.

Efficacy & effects

Treatment of neuropathic pain and fibromyalgia; adjunctive treatment of partial seizures

  • Peripheral neuropathic pain
  • central neuropathic pain
  • partial seizures with or without secondary generalization
  • fibromyalgia.
View approved original text

This medication is used to treat peripheral and central neuropathic pain in adults. It is also utilized as an adjunctive treatment for partial seizures in patients with epilepsy, both with and without secondary generalization. Additionally, it is effective in alleviating symptoms in patients with fibromyalgia. This medication aids in the improvement of symptoms associated with various neurological disorders.

How to take

Adult dose

This medicine is administered orally, with or without food, in 2 divided doses per day, for a total daily dose of pregabalin. Since this medicine is primarily excreted by the kidneys, the dose should be adjusted in patients with impaired renal function. (See “5. Patients with Renal Impairment”) 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of each patient, the dose may be increased to 300 mg/day after 3 to 7 days. If necessary, the dose may then be increased at 7-day intervals to a maximum of 600 mg/day. 2) Central neuropathic pain Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of each patient, the dose may be increased to 300 mg/day after 1 week. After an additional 1 week, the dose may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered. (See “4. Discontinuation of Treatment”) 2. Epilepsy Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of each patient, the dose may be increased to 300 mg/day after 1 week. If necessary, the dose may then be increased at 7-day intervals to a maximum of 600 mg/day. 3. Fibromyalgia The recommended dose of this medicine for fibromyalgia is 300 mg to 450 mg/day. The initial dose is 75 mg twice daily (150 mg/day), and based on efficacy and tolerability, it may be increased within 1 week to 150 mg twice daily (300 mg/day). For patients who do not experience sufficient benefit at a dose of 300 mg/day, the dose may be increased within 1 week to 225 mg twice daily (450 mg/day). Clinical studies have also been conducted at a dose of 600 mg/day; however, there is no evidence of additional benefit or adequate tolerability at this dose. In view of the dose-dependent adverse reactions, doses exceeding 450 mg/day are not recommended. 4. Discontinuation of Treatment Based on current clinical experience, if treatment with this medicine is discontinued, it should be tapered gradually over at least 1 week. 5. Patients with Renal Impairment After entering the systemic circulation, this medicine is primarily excreted by the kidneys unchanged. Since the clearance of this medicine is directly affected by creatinine clearance, dose reduction in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the formula below. This medicine is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients receiving hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, an immediate supplemental dose should be administered after each 4-hour hemodialysis session. [Table 1]. Pregabalin dosage based on renal function Creatinine clearance (CLcr), (mL/min) ≥60: Initial dose 150 (mg/day), maximum dose 600 (mg/day), BID or TID Creatinine clearance (CLcr), (mL/min) ≥30 -<60: Initial dose 75 (mg/day), maximum dose 300 (mg/day), BID or TID Creatinine clearance (CLcr), (mL/min) ≥15 -<30: Initial dose 25-50 (mg/day), maximum dose 150 (mg/day), QD or BID Creatinine clearance (CLcr), (mL/min) <15: Initial dose 25 (mg/day), maximum dose 75 (mg/day), QD Supplemental dose after hemodialysis: Initial dose 25, maximum dose 100, single dose b TID = total daily dose administered in 3 divided doses BID = total daily dose administered in 2 divided doses QD = administered once daily a: The total daily dose (mg/day) should be administered in divided doses as specified in the dosing regimen. b: A supplemental dose refers to an additional dose administered as a single dose. 6. Patients with Hepatic Impairment No dose adjustment is necessary in patients with hepatic impairment. 8. Older adults (aged 65 years or older) Dose reduction may be necessary in older adults with impaired renal function.

Child dose

7. Pediatric and adolescent patients Children under 12 years of age: Administration is not recommended because there are insufficient safety and efficacy data. Adolescent patients aged 12~17 years: Administration is not recommended because there are insufficient safety and efficacy data.

Precautions

This drug may increase the risk of suicidal thoughts or behavior, so careful monitoring is required for signs of depression or mood changes during treatment. It should not be used in patients with hypersensitivity to this medication. Diabetic patients should be cautious as weight gain may necessitate adjustments in blood sugar control medications. If symptoms of angioedema occur, discontinue use immediately and consult a healthcare professional. Elderly patients should be particularly cautious at the start of treatment due to the risk of falls from dizziness or drowsiness. Visual disturbances or changes in eyesight may occur, which may improve upon discontinuation of the medication. Caution should be exercised when switching to this drug from monotherapy, as sudden withdrawal may result in withdrawal symptoms such as insomnia, headaches, and anxiety. There is a potential for drug abuse or dependence, so caution is advised in patients with a history of central nervous system drug abuse. Patients with impaired kidney function may require dosage adjustments. Patients with heart disease should use this drug cautiously due to the risk of congestive heart failure. Caution should be exercised when using this drug in combination with opioid analgesics as it may increase the risk of central nervous system depression. Patients with compromised respiratory function or elderly patients may have an elevated risk of severe respiratory depression and may require dosage adjustments. During early pregnancy, there is a risk of fetal malformations; thus, this drug should not be used in pregnant women, and fertile women should use effective contraception. Breastfeeding women should consider discontinuing breastfeeding or the medication as it may transfer into breast milk and affect the infant. Activities requiring alertness such as driving or operating machinery should be avoided until dizziness and drowsiness subside. Severe skin reactions may rarely occur; thus, discontinue use immediately if any skin abnormalities occur. In the case of overdose, symptoms such as confusion, drowsiness, and depression may appear, and treatment like dialysis may be required if necessary. Store out of reach of children, and avoid transferring to other containers as it may not maintain quality.

Side effects

  • Suicidal thoughts
  • suicidal behavior
  • depression
  • abnormal changes in mood and behavior
  • angioedema
  • facial swelling
  • perioral edema
  • upper airway edema
  • dizziness
  • drowsiness
Show 182 more
  • loss of consciousness
  • confusion
  • mental disorder
  • blurred vision
  • changes in vision
  • insomnia
  • headache
  • nausea
  • anxiety
  • diarrhea
  • influenza-like illness
  • restlessness
  • melancholy
  • pain
  • seizures
  • hyperhidrosis
  • misuse
  • abuse
  • dependence
  • respiratory depression
  • impaired respiratory function
  • severe respiratory depression
  • rhinitis
  • neutropenia
  • increased appetite
  • decreased appetite
  • hypoglycemia
  • confusion
  • disorientation
  • irritability
  • feelings of happiness
  • decreased libido
  • depersonalization
  • sexual arousal disorder
  • restlessness
  • mood swings
  • emotional decline
  • emotional elevation
  • difficulty finding appropriate terms
  • hallucinations
  • abnormal dreams
  • increased libido
  • panic attacks
  • impulsivity
  • flatness
  • ataxia
  • movement coordination disorder
  • balance disorders
  • amnesia
  • attention deficit
  • memory impairment
  • tremor
  • dysarthria
  • sensory abnormalities
  • sensory loss
  • sedation
  • drowsiness syndrome
  • cognitive impairment
  • ocular nystagmus
  • speech disorders
  • tics
  • decreased reflexes
  • movement abnormalities
  • psychomotor agitation
  • positional dizziness
  • hypersensitivity
  • burning sensation
  • tremor during activity
  • syncope
  • clouding of consciousness
  • motor retardation
  • olfactory abnormalities
  • loss of taste
  • writing difficulty
  • diplopia
  • vertigo
  • hyperacusis
  • first-degree AV block
  • tachycardia
  • sinus bradycardia
  • sinus tachycardia
  • sinus arrhythmia
  • hypotension
  • hypertension
  • flushing
  • facial flushing
  • peripheral coldness
  • dyspnea
  • epistaxis
  • cough
  • nasal congestion
  • rhinitis
  • snoring
  • throat tension
  • nasal dryness
  • vomiting
  • abdominal distension
  • constipation
  • dry mouth
  • bloating
  • excessive salivation
  • gastroesophageal reflux disease
  • oral sensory loss
  • ascites
  • dysphagia
  • pancreatitis
  • sweating
  • papular rash
  • urticaria
  • cold sweat
  • muscle cramps
  • arthralgia
  • back pain
  • limb pain
  • cervical spasms
  • joint swelling
  • myalgia
  • muscle spasms
  • neck pain
  • muscle rigidity
  • rhabdomyolysis
  • urination disorders
  • urinary incontinence
  • decreased urine output
  • renal failure
  • erectile dysfunction
  • delayed ejaculation
  • sexual dysfunction
  • dysmenorrhea
  • amenorrhea
  • breast pain
  • nipple discharge
  • breast hypertrophy
  • peripheral edema
  • edema
  • gait abnormalities
  • falls
  • intoxication feeling
  • sensory disturbances
  • fatigue
  • chest tightness
  • generalized edema
  • pain
  • fever
  • chills
  • weakness
  • thirst
  • weight gain
  • increased alanine aminotransferase
  • increased serum creatine phosphokinase
  • increased aspartate aminotransferase
  • increased blood sugar
  • decreased platelet count
  • decreased serum potassium
  • increased serum creatinine
  • decreased white blood cell count
  • hypersensitivity
  • allergic reactions
  • headache
  • keratitis
  • congestive heart failure
  • pulmonary edema
  • tongue swelling
  • itching
  • Stevens-Johnson syndrome
  • toxic epidermal necrolysis
  • urinary retention
  • gynecomastia
  • lethargy
  • delirium
  • paralysis (facial paralysis)
  • mood disorder
  • drowsiness
  • confused state
  • agitation
  • restlessness
  • exacerbation of seizures
  • gastrointestinal disorders
  • tinnitus
  • sleep disorders
  • skin diseases
  • bloody stools

Not everyone experiences these, and they can vary from person to person.

Storage

This medication may be sensitive to air or moisture, so it is important to store it in a tightly sealed container. Additionally, it should be kept in a cool place, between 15°C to 30°C, to maintain its effectiveness.

Appearance and packaging

Appearance

A hard capsule with a reddish-brown upper part and a white lower part containing white powder.

Package unit

30 capsules/bottle, 100 capsules/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.